- Home
- NMS vs CVM Comparison
NMS vs CVM Comparison
Compare NMS & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- CVM
- Stock Information
- Founded
- NMS 1993
- CVM 1983
- Country
- NMS United States
- CVM United States
- Employees
- NMS N/A
- CVM N/A
- Industry
- NMS Finance Companies
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMS Finance
- CVM Health Care
- Exchange
- NMS Nasdaq
- CVM Nasdaq
- Market Cap
- NMS 71.2M
- CVM 60.9M
- IPO Year
- NMS N/A
- CVM 1987
- Fundamental
- Price
- NMS $11.82
- CVM $8.20
- Analyst Decision
- NMS
- CVM
- Analyst Count
- NMS 0
- CVM 0
- Target Price
- NMS N/A
- CVM N/A
- AVG Volume (30 Days)
- NMS 12.0K
- CVM 72.3K
- Earning Date
- NMS 01-01-0001
- CVM 08-14-2025
- Dividend Yield
- NMS 4.11%
- CVM N/A
- EPS Growth
- NMS N/A
- CVM N/A
- EPS
- NMS N/A
- CVM N/A
- Revenue
- NMS N/A
- CVM N/A
- Revenue This Year
- NMS N/A
- CVM N/A
- Revenue Next Year
- NMS N/A
- CVM N/A
- P/E Ratio
- NMS N/A
- CVM N/A
- Revenue Growth
- NMS N/A
- CVM N/A
- 52 Week Low
- NMS $9.21
- CVM $1.98
- 52 Week High
- NMS $12.18
- CVM $32.70
- Technical
- Relative Strength Index (RSI)
- NMS 47.33
- CVM 38.86
- Support Level
- NMS $11.73
- CVM $8.15
- Resistance Level
- NMS $11.85
- CVM $9.35
- Average True Range (ATR)
- NMS 0.15
- CVM 0.59
- MACD
- NMS -0.02
- CVM -0.16
- Stochastic Oscillator
- NMS 35.48
- CVM 2.40
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.